A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration ...

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price ...

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque ...

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who ...

Number 1: The competitive landscape for bone health treatments in the US has intensified with the FDA approval of Bildyos ...

Gary Fanjiang, MD, MBA, MS, is the vice president of global development at Amgen, where he leads research and development activities for the Biosimilars Business Unit. He oversees the nonclinical, ...

After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive ...

The FDA approved Celltrion USA’s Zymfentra (infliximab-dyyb), the world’s first and only subcutaneous infliximab product. Zymfentra is approved as a novel drug, and its development is based on ...